Can you describe your experience treating patients with type 2 diabetes and your knowledge of the Phase 3b SWITCH 2 trial?

Tresiba experienced a statistically significant reduction in hypoglycemic events (186 events per 100 patient years exposed) compared to insulin glargine (265 events per 100 patient years exposed), achieving its primary efficacy endpoint of at least a 30% reduction in such events. What is the clinical relevance of this result?

Is this an appropriate primary endpoint for the study?

Tresiba also achieved statistical significance in its secondary endpoint, the observed rate of severe or blood glucose symptomatic nocturnal confirmed hypoglycemia in the maintenance period. Tresiba's rate was 55 events/100 patients years versus 94 events/100 patients years for insulin glargine. What is the clinical relevance of this result?

Is this an appropriate secondary endpoint for the study?

Another secondary endpoint is the proportion of patients experiencing severe hypoglycemia during the maintenance period. The rate was reduced 51% with Tresiba, which was statistically valid but not significant. What is the clinical relevance of this result?

Is this an appropriate secondary endpoint for this study?

How does the fact that Tresiba failed to reach statistical significance in this endpoint affect its chances of reaching the market?

What current treatment options are used for T2D?

How many patients would you say are seeking treatment options in the United States?

How does Tresiba compare to current treatment options? 

What percentage of T2D patients would you estimate will be prescribed Tresiba?